Compounds and Products Sample Clauses

Compounds and Products. All Compounds and Products with respect to a Terminated Program, i.e., CNS Penetrants and CNS Penetrant Products for the CNS Program and Non-CNS Penetrants and Non-CNS Penetrant Products for the Non-CNS Program, (each, a “Terminated Compound” and “Terminated Product,” respectively) shall cease to be Compounds and Products under this Agreement.
Sample 1
AutoNDA by SimpleDocs
Compounds and Products. Subject to the terms and conditions of this Agreement, Arcturus hereby grants to JPI an exclusive license under the Arcturus Technology and Arcturus’ interest in the Joint Patent Rights to Exploit NA Therapeutics, Licensed Compounds and Licensed Products in the Field worldwide as identified and selected and on the terms and conditions set forth in this Agreement. The license granted under this Section 4.1 is exclusive even as to Arcturus, except as necessary for Arcturus to exercise its rights and perform its obligations under the Joint Research Plan. The license granted under this Section 4.1 includes the right for JPI to sublicense to its Affiliates and to Third Parties. This license includes the right to utilize NA Therapeutics, Licensed Products and Licensed Compounds in Combination Products that incorporate other active pharmaceutical ingredients that are not Licensed Compounds and in Bundled Products that incorporate other products that are neither Licensed Compounds nor Combination Products. For clarity, NA Therapeutics, Licensed Compounds and Licensed Products in the Option Disease Areas are not licensed pursuant to this Section 4.1 unless and until such time as an Option in an Option Disease Area is exercised by JPI pursuant to Section 4.2. For clarity, no license or Option rights are granted pursuant to this Article 4 with respect to NA Therapeutics that are not also subject to the Exclusivity obligations pursuant to Section 1.7 (i.e., with respect to NA Therapeutics for which the obligations under Sections 1.7.1 and 1.7.3 do not apply, no license rights are granted to JPI and no restrictions on exclusivity shall apply pursuant to this Agreement). ***Confidential Treatment Requested
Sample 1
Compounds and Products. Pharmacopeia agrees to grant, and ----------------------------- hereby grants to SPL an exclusive license under the Pharmacopeia Technology and Pharmacopeia's interest in the Collaboration Technology (exclusive even as to Pharmacopeia and its Affiliates), to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.
Sample 1
Compounds and Products. Pharmacopeia agrees to grant, and ----------------------------- hereby grants to Schering an exclusive license under the Pharmacopeia Technology and Pharmacopeia's interest in the Collaboration Technology (exclusive even as to Pharmacopeia and its Affiliates), to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.
Sample 1

Related to Compounds and Products

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Proceeds and Products All proceeds, including insurance proceeds, and products of the items of Credit Security described or referred to in Sections 2.1.1 through 2.1.14 and, to the extent not included in the foregoing, all Distributions with respect to the Pledged Securities.

  • Product The term “

  • Products 1.1. The information (including but not limited to the quantity, rated hashrate, unit price (“Unit Price”), total price for one item (“Total Price (One Item)”), total price for all the items (“Total Purchase Price”) of Products to be purchased by Party B from Party A is as follows (“Products”):

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Combination Products If a LICENSED PRODUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the Licensed Product components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

Time is Money Join Law Insider Premium to draft better contracts faster.